
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is on track for success due to their innovative approach to treating neurodegenerative diseases, strong financial position with a valuation of $520M and a potential $540M in peak annual sales for ZUNVEYL, and the company's ability to build a strong commercial team and secure licensing partnerships. Risks include potential competition, slow market uptake, and setbacks in clinical testing. The recent settlement agreement eliminates future royalty and milestone payments, providing a more streamlined financial position. With additional contracting expected in the near-term and modest revisions to our forecasts, we maintain a Buy rating and a 12-month price target of $18.
Bears say
Alpha Cognition is expected to face challenges in its commercial development program for ZUNVEYL due to potential pricing pressures, payor push-back, and competition from generic and other branded products. The company's current financial results show a net loss in the first quarter of 2026, and while its revenue projections are positive, there is still a risk of slower-than-expected market uptake. Furthermore, the potential dilution risk for long-term shareholders is a concern, and the success of the ongoing clinical trials and the timely launch of ZUNVEYL are key factors for the company's future performance.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares